A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas
1454-0015
Phase 1 other active
Quick answer
A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas for colorectal carcinoma (CRC) is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- colorectal carcinoma (CRC)
- Phase
- Phase 1
- Modality
- other
- Status
- active